Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ReShape Lifesciences Inc. RSLS
$2.40
-$0.01 (-0.62%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
7388037.00000000
-
week52high
52.50
-
week52low
2.21
-
Revenue
11240000
-
P/E TTM
0
-
Beta
1.44498200
-
EPS
-119.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мая 2023 г. в 12:30
Описание компании
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Alliance Global Partners | Buy | Buy | 26 мая 2022 г. |
| Maxim Group | Buy | 08 окт 2021 г. | |
| Ladenburg Thalmann | Neutral | Buy | 03 авг 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| STANKOVICH THOMAS | D | 325404 | 2213 | 01 дек 2022 г. |
| STANKOVICH THOMAS | D | 327617 | 5144 | 01 дек 2022 г. |
| STANKOVICH THOMAS | D | 332761 | 364756 | 28 ноя 2022 г. |
| STANKOVICH THOMAS | A | 697517 | 364756 | 17 ноя 2022 г. |
| STANKOVICH THOMAS | D | 332761 | 2510 | 04 ноя 2022 г. |
| STANKOVICH THOMAS | D | 335271 | 5883 | 04 ноя 2022 г. |
| STANKOVICH THOMAS | D | 338670 | 2484 | 04 окт 2022 г. |
| STANKOVICH THOMAS | D | 341154 | 5809 | 04 окт 2022 г. |
| STANKOVICH THOMAS | D | 346963 | 4828 | 06 сент 2022 г. |
| STANKOVICH THOMAS | D | 351791 | 4728 | 05 авг 2022 г. |
Новостная лента
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update
GlobeNewsWire
11 мая 2023 г. в 08:30
SAN CLEMENTE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2023, including a corporate update on Monday, May 15, 2023, after market.
ReShape Lifesciences Inc. (RSLS) Q4 2022 Earnings Call Transcript
Seeking Alpha
29 апр 2023 г. в 13:12
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q4 2022 Earnings Conference Call April 25, 2023 4:30 PM ET Company Participants Michael Miller - Investor Relations Paul Hickey - President & Chief Executive Officer Thomas Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences' Year-End 2022 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
GlobeNewsWire
27 апр 2023 г. в 08:30
SAN CLEMENTE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will present data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in a poster at the Keystone Symposia on Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics, being held in Palm Springs, CA, May 1 – 4, 2023.
Penny Stocks To Buy? 4 To Watch Now After Big News This Week
PennyStocks
03 апр 2023 г. в 12:52
Penny stocks to watch with news this week. Are they a buy now or should you avoid them entirely?
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call
GlobeNewsWire
28 мар 2023 г. в 21:50
SAN CLEMENTE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will delay its year ended December 31, 2022 earnings release and conference call, previously scheduled for 8:00 am ET on March 29, 2022. The delay is required to allow the company additional time to complete its year end audited financial information.